Results 51 to 60 of about 43,946 (263)

Educating Patients on Cannabidiol (CBD) [PDF]

open access: yes, 2019
As the popularity of cannabidiol (CBD) increases, more patients are interested in trying a natural adjunct to more standard medications. But with no current FDA oversight, an estimated 70% of CBD products could be mislabeled.
Pratt, Catherine G
core   +1 more source

Pricing Dynamics in the US Hemp Market: A Vertical Price Transmission Analysis of the Hemp Value Chain

open access: yesAgribusiness, EarlyView.
ABSTRACT The US hemp market is a new and nascent industry that has been devoid of research for about half a century. This study examined the effects of exogenous shock on price at each phase of the value chain—Farm (hemp biomass), and its impact on prices at other phases of the value chain—Intermediary Processor (crude cannabidiol hemp) and Final ...
Solomon Odiase   +2 more
wiley   +1 more source

Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer

open access: yesFrontiers in Pharmacology, 2019
Cannabinoids exhibit anti-inflammatory and antitumorigenic properties. Contrary to most cannabinoids present in the Cannabis plant, some, such as O-1602 and abnormal cannabidiol, have no or only little affinity to the CB1 or CB2 cannabinoid receptors and
Andrea Tomko   +9 more
doaj   +1 more source

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study

open access: yesBrain Sciences, 2022
Δ9-Tetrahydrocannabinol is the main psychoactive component of cannabis and cannabidiol is purportedly responsible for many of the medicinal benefits. The effects of Δ9-tetrahydrocannabinol and cannabidiol in younger populations have been well studied ...
Thorsten Rudroff   +4 more
doaj   +1 more source

Evidence for the use of ‘‘medical marijuana’’ in psychiatric and neurologic disorders [PDF]

open access: yes, 2017
Introduction: Cannabis is listed as a Schedule I substance under the Controlled Substances Act of 1970, meaning the US federal government defines it as an illegal drug that has high potential for abuse and no established medical use; however, half of the
Noel, Christopher
core   +2 more sources

Cannabis through the looking glass: chemo- and enantio-selective separation of phytocannabinoids by enantioselective ultra high performance supercritical fluid chromatography [PDF]

open access: yes, 2017
By using the Inverted Chirality Columns Approach (ICCA) we have developed an enantioselective UHPSFC method to determine the enantiomeric excess (ee) of (-)-Δ(9)-THC in medicinal marijuana (Bedrocan®).
Cavazzini, A   +7 more
core   +2 more sources

Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate

open access: yesAutism Research, EarlyView.
ABSTRACT Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits, repetitive behaviors, and sensory abnormalities. Sodium valproate (VPA) exposure during embryonic development is a well‐established preclinical model for ASD, leading to increased oxidative stress in the developing brain, including ...
Karla C. M. Costa   +13 more
wiley   +1 more source

DETERMINACIÓN DE LA CAPACIDAD ANTIOXIDANTE DE UNA CREMA ELABORADA CON EXTRACTO ISOLADO DE CANNABIDIOL DE Cannabis sativa L. (CÁÑAMO)

open access: yesinfoANALITÍCA
En la presente investigación se determinó la capacidad antioxidante de una crema cosmética facial, elaborada a partir del extracto aislado (isolado) de cannabidiol. Para establecer la capacidad antioxidante.
Nataly Arciniegas S.   +3 more
doaj   +1 more source

Characterisation of inverse agonism of the orphan-G protein-coupled receptor GPR52 by cannabinoid ligands Cannabidiol and O-1918

open access: yesHeliyon, 2021
The identification of cannabinoid ligands Cannabidiol and O-1918 as inverse agonists of the orphan receptor GPR52 is reported. Detailed characterisation of GPR52 pharmacology and modelling of the proposed receptor interaction is described.
Lisa A. Stott   +12 more
doaj   +1 more source

A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis [PDF]

open access: yes, 2019
Background: Persistent and/or recurrent inflammatory processes are the main factor leading to multiple sclerosis (MS) lesions. The composite ultramicronized palmitoylethanolamide, an endogenous N-acylethanolamine, combined with the flavonoid luteolin ...
Barbierato, M.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy